Tim-Henrik Bruun
Overview
Explore the profile of Tim-Henrik Bruun including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
12
Citations
94
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Bruun T, Dietrich J, Klingseisen A, Bogdahn U
Front Cell Neurosci
. 2023 May;
17:1200639.
PMID: 37187608
No abstract available.
2.
Kozole J, Heydn R, Wirkert E, Kuspert S, Aigner L, Bruun T, et al.
Pharmaceutics
. 2022 Sep;
14(9).
PMID: 36145606
The hematopoietic granulocyte-colony stimulating growth factor (G-CSF, filgrastim) is an approved drug in hematology and oncology. Filgrastim's potential in neurodegenerative disorders is gaining increasingly more attention, as preclinical and early...
3.
Peters S, Wirkert E, Kuespert S, Heydn R, Johannesen S, Friedrich A, et al.
Pharmaceutics
. 2022 Jan;
14(1).
PMID: 35057094
The capability of the adult central nervous system to self-repair/regenerate was demonstrated repeatedly throughout the last decades but remains in debate. Reduced neurogenic niche activity paralleled by a profound neuronal...
4.
Peters S, Kuespert S, Wirkert E, Heydn R, Jurek B, Johannesen S, et al.
Neurotherapeutics
. 2021 Apr;
18(3):1963-1979.
PMID: 33860461
Adult neurogenesis is a target for brain rejuvenation as well as regeneration in aging and disease. Numerous approaches showed efficacy to elevate neurogenesis in rodents, yet translation into therapies has...
5.
Johannesen S, Huie J, Budeus B, Peters S, Wirth A, Iberl S, et al.
Front Neurol
. 2021 Apr;
12:616289.
PMID: 33815246
Developing an integrative approach to early treatment response classification using survival modeling and bioinformatics with various biomarkers for early assessment of filgrastim (granulocyte colony stimulating factor) treatment effects in amyotrophic...
6.
Kuespert S, Heydn R, Peters S, Wirkert E, Meyer A, Sieborger M, et al.
Int J Mol Sci
. 2020 Mar;
21(6).
PMID: 32178467
Antisense Oligonucleotides (ASOs) are an emerging drug class in gene modification. In our study we developed a safe, stable, and effective ASO drug candidate in locked nucleic acid (LNA)-gapmer design,...
7.
Wirth A, Johannesen S, Khomenko A, Baldaranov D, Bruun T, Wendl C, et al.
J Magn Reson Imaging
. 2018 Dec;
50(2):552-559.
PMID: 30569457
Background: MRI fluid-attenuated inversion recovery (FLAIR) studies reported hyperintensity in the corticospinal tract and corpus callosum of patients with amyotrophic lateral sclerosis (ALS). Purpose: To evaluate the lesion segmentation toolbox...
8.
Johannesen S, Budeus B, Peters S, Iberl S, Meyer A, Kammermaier T, et al.
Front Neurol
. 2018 Dec;
9:971.
PMID: 30534107
To evaluate safety, tolerability and feasibility of long-term treatment with Granulocyte-colony stimulating factor (G-CSF), a well-known hematopoietic stem cell factor, guided by assessment of mobilized bone marrow derived stem cells...
9.
Wirth A, Khomenko A, Baldaranov D, Kobor I, Hsam O, Grimm T, et al.
Front Neurol
. 2018 Aug;
9:614.
PMID: 30104996
Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative process affecting upper and lower motor neurons as well as non-motor systems. In this study, precentral and postcentral cortical thinning detected by...
10.
Peters S, Zitzelsperger E, Kuespert S, Iberl S, Heydn R, Johannesen S, et al.
Front Neurol
. 2018 Jan;
8:669.
PMID: 29326641
Amyotrophic lateral sclerosis (ALS) represents a fatal orphan disease with high unmet medical need, and a life time risk of approx. 1/400 persons per population. Based on increasing knowledge on...